NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $14.28, above its previous 52-week high of $14.20 with 847,865 shares traded as of 11:32 a.m. ET. Average volume has been 660,300 shares over the past 30 days.
Optimer has a market cap of $648 million and is part of the
industry. Shares are up 23.7% year to date as of the close of trading on Thursday.
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. It develops products that treat gastrointestinal infections and related diseases. The company has a P/E ratio of 77.7, below the average drugs industry P/E ratio of 82.2 and above the S&P 500 P/E ratio of 17.7.
- Practice your OPTR trading strategies and win cash in our stock game.
TheStreet Ratings rates Optimer as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full
52-week high stocks
or get investment ideas from our